Abstract:
To investigate the potential molecular mechanism of galactopoietic pill in the treatment of hypogalactia, the main active components and their potential target proteins in hypogalactia treatment were profiled in this study with the aid of the network pharmacology.The active component-protein interaction network was constructed, and the molecular docking verification was carried out by computer simulation. Results showed that galactopoietic pill mainly includes twelve bioactive components (quercetin, luteolin, geranitin, kaempferol, folic acid, β-sitosterol, etc.) and sixteen key target proteins (STAT3, MAPK1, JAK2, EGFR, ESR1, STAT5A, etc.). The enrichment analysis and screening illustrated that the target proteins of the active components in galactopoietic pill are enriched in multiple biological pathways, such as prolactin signaling pathway, estrogen signaling pathway, AMPK signaling pathway and cAMP signaling pathway. The molecular docking verification showed that quercetin, β-sitosterol and luteolin have strong binding ability with STAT3, MAPK1, ESR1 and EGFR, which affect the growth of mammary epithelial cells and play a key role in hypogalactia treatment by regulating transcription factors, kinases, estrogen receptor proteins and epidermal growth factor receptor proteins. The results preliminarily reveal the multi-components, multi-targets and multi-pathways mechanism of galactopoietic pill in hypogalactia treatment and provide a reference for hypogalactia treatment.
